Schrodinger, Inc. (SDGR) Form 10-Q — Nov 4, 2026
Schrödinger filed its Q3 2026 10-Q showing quarterly revenue of $64.5 million, up 18.7% year-over-year, with drug discovery revenue nearly doubling to $24.2 million. Net loss was $37.7 million in the quarter and $91.8 million for the nine months, an improvement from $135.8 million a year earlier, with Q3 EPS of $(0.50). The company ended the quarter with $373.4 million in cash, cash equivalents, restricted cash and marketable securities, bolstered by roughly $57.2 million received from Eli Lilly's acquisition of co-founded Ajax Therapeutics.
Key figures
- Revenue
- 181967000
- Revenue Yoy
- Q3 revenue +18.7% YoY ($64.5M vs $54.3M); nine-month revenue $182.0M vs $168.6M
- Total Assets
- 611940000
- Cash Position
- 373378000
- Q3 2026 revenue
- 64491000
- Ajax liquidity payment
- 57200000
- Atm capacity remaining
- 241132000
- Software revenue 9m 2026
- 106257000
- Norse remaining milestones
- 1424000000
- Operating cash flow 9m 2025
- 29992000
- Drug discovery revenue 9m 2026
- 70052000
- Remaining performance obligations
- 186670000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.